OBJECTIVE: The direct role of leptin in vascular disease remains controversial. The objective of this study was to examine the effects of leptin treatment on atherosclerosis and thrombosis in atherosclerotic-prone mice. METHODS AND RESULTS: Sixteen-week-old, male apolipoprotein E-deficient mice were treated with injections of recombinant leptin (125 microg per day IP; n=10) or vehicle (n=10) for 4 weeks. Leptin treatment resulted in reduced epididymal fat (352+/-30.7 versus 621+/-61.5 mg; P=0.005) and fasting insulin (0.57+/-0.25 versus 1.7+/-0.22 ng/mL; P=0.014). Despite these metabolic benefits, leptin treatment resulted in an increase in atherosclerosis (8.0+/-0.95% versus 5.4+/-0.59% lesion surface coverage; P<0.05). Leptin treatment also resulted in a shortened time to occlusive thrombosis after vascular injury (21+/-2.1 versus 34.6+/-5.4 minutes; P=0.045). CONCLUSIONS: These studies indicate that exogenous leptin promotes atherosclerosis and thrombosis and support the concept that elevations of leptin may increase the risk for cardiovascular disease.
OBJECTIVE: The direct role of leptin in vascular disease remains controversial. The objective of this study was to examine the effects of leptin treatment on atherosclerosis and thrombosis in atherosclerotic-prone mice. METHODS AND RESULTS: Sixteen-week-old, male apolipoprotein E-deficientmice were treated with injections of recombinant leptin (125 microg per day IP; n=10) or vehicle (n=10) for 4 weeks. Leptin treatment resulted in reduced epididymal fat (352+/-30.7 versus 621+/-61.5 mg; P=0.005) and fasting insulin (0.57+/-0.25 versus 1.7+/-0.22 ng/mL; P=0.014). Despite these metabolic benefits, leptin treatment resulted in an increase in atherosclerosis (8.0+/-0.95% versus 5.4+/-0.59% lesion surface coverage; P<0.05). Leptin treatment also resulted in a shortened time to occlusive thrombosis after vascular injury (21+/-2.1 versus 34.6+/-5.4 minutes; P=0.045). CONCLUSIONS: These studies indicate that exogenous leptin promotes atherosclerosis and thrombosis and support the concept that elevations of leptin may increase the risk for cardiovascular disease.
Authors: Aaron S Kelly; Andrea M Metzig; Sarah Jane Schwarzenberg; Anne L Norris; Claudia K Fox; Julia Steinberger Journal: Metab Syndr Relat Disord Date: 2012-01-04 Impact factor: 1.894
Authors: Diana M Shih; Yu-Rong Xia; Xu-Ping Wang; Susanna S Wang; Noam Bourquard; Alan M Fogelman; Aldons J Lusis; Srinivasa T Reddy Journal: Circ Res Date: 2007-03-22 Impact factor: 17.367
Authors: E Martínez-Martínez; M Miana; R Jurado-López; M V Bartolomé; F V Souza Neto; M Salaices; N López-Andrés; V Cachofeiro Journal: Int J Obes (Lond) Date: 2014-03-03 Impact factor: 5.095
Authors: Victoria L King; Nicholas W Hatch; Huei-Wei Chan; Marcielle C de Beer; Frederick C de Beer; Lisa R Tannock Journal: Obesity (Silver Spring) Date: 2009-06-04 Impact factor: 5.002
Authors: Miina K Ohman; Yuechun Shen; Chinyere I Obimba; Andrew P Wright; Mark Warnock; Daniel A Lawrence; Daniel T Eitzman Journal: Circulation Date: 2008-01-22 Impact factor: 29.690